In this phase 3 trial of patients with platinum-resistant ovarian cancer, relacorilant combined with nab-paclitaxel significantly improved overall survival by extending median survival by 4.1 months compared with nab-paclitaxel alone. The combination showed manageable safety without new safety signals, supporting its use as a new standard of care in this population.
Study
|
Open-label, randomised, controlled, phase 3 trial [ROSELLA, NCT05257408] |
| Platinum-resistant ovarian cancer (n=381) |
| Relacorilant + nab-paclitaxel (n=188) vs nab-paclitaxel (n=193)
|
Efficacy
|
mOS: 16.0 mos vs 11.9 mos (relacorilant+nab-paclitaxel vs. nab-paclitaxel) (HR 0.65 [0.51-0.83]) |
| 18-mo OS: 46% vs 27% |
| Second PFS: HR 0.73 [0.58-0.90]
|
Safety
|
Grade 3+AEs: Neutropenia (44% vs 25%), Anaemia (18% vs 9%), Fatigue (9% vs 2%), Nausea (4% vs 3%), Diarrhoea (4% vs 2%) |
| Treatment discontinuation due to AE: 10% vs 8% |
| Deaths on treatment due to AE: 2% (relacorilant combination)
|
Lancet 2026;407:1513-1524
http://doi.org/10.1016/S0140-6736(26)00462-9
Reviewed by Ulas D. Bayraktar, MD on May 15, 2026
